Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection ...Middle East

--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research...

Hence then, the article about ascletis announces u s fda approval of conducting a phase iia clinical trial for asc10 to treat respiratory syncytial virus infection was published today ( Tuesday 31/01/2023 - 12:49 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection )

Also on site :

• Kentucky congressman announces death of longtime staffer, campaign manager
• EastEnders airs reunion for 'Witches of Walford', shock arrest, and Cindy & Max hook-up for Christmas 2025
• Camarillo man arrested after stolen camera reactivated and installed on the exterior of a home